BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 7512182)

  • 1. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
    Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
    Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
    Tanaka Y; Tanaka R; Hoshino H
    Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
    Tanaka Y; Yasumoto M; Nyunoya H; Ogura T; Kikuchi M; Shimotohno K; Shiraki H; Kuroda N; Shida H; Tozawa H
    Int J Cancer; 1990 Oct; 46(4):675-81. PubMed ID: 1698731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
    Jacobson S; Reuben JS; Streilein RD; Palker TJ
    J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.
    Londos-Gagliardi D; Armengaud MH; Freund F; Dalibart R; Moze E; Huet S; Legrand E; Guillemain BJ
    Leukemia; 1997 Apr; 11 Suppl 3():38-41. PubMed ID: 9209290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
    Hadlock KG; Yang Q; Rowe J; Foung SK
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
    Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
    J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition by human sera of a variable region of the surface glycoprotein of HTLV-I.
    Edouard E; Londos-Gagliardi D; Busetta B; Geoffre S; Dalbon P; Moreau JP; Guillemain B
    Leukemia; 1994 Apr; 8 Suppl 1():S65-7. PubMed ID: 8152306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
    Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
    Hadlock KG; Rowe J; Foung SK
    J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.